Imbruvica (ibrutinib)

pCPA File Number: 23570
Negotiation Status:
Active Negotiation
Indication(s):
Venclexta, in combination with ibrutinib, for the treatment of adult patients with relapsed or
refractory mantle cell lymphoma
Sponsor/Manufacturer:
Janssen Inc.
CDA-AMC Project Number:
PC0402-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable